Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Neda Alrawashdh, PharmD, Ali McBride, PharmD, MS, Marion Slack, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136358

Published: 2020

Journal Articles

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Trace Bartels, BS, Logan Moore, Neda Alrawashdh, PharmD, Abhijeet Kumar, Ivo Abraham, PhD RN, Daniel O. Persky, MD, Ali McBride, PharmD, MS

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-141651

Published: 2020

Journal Articles

Economic Evaluation of Daratumumab and Pomalidomide and Dexamethasone Versus Isatuximab and Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Neda Alrawashdh, PharmD, Abdulaali Almutairi, Ali McBride, PharmD, MS, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136348

Published: 2020

Journal Articles

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Ali McBride, PharmD, MS, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-142749

Published: 2020

Journal Articles

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Ali McBride, PharmD, MS, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136810

Published: 2020

Journal Articles

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Logan Moore, Trace Bartels, BS, Daniel O. Persky, MD, Abhijeet Kumar, Ivo Abraham, PhD RN, Lauren Sanders, PharmD, Alicia Ortega, PharmD, Alyssa Henglefelt, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 5353.

https://doi.org/10.1182/blood-2019-132148

Published: 2019

Journal Articles

Recurrent Venous Thromboembolism (VTE), Major Bleeding (MB), and Associated Cost of Treatment with Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulant (DOAC) in High Risk Patients with Gastrointestinal (GI) Malignancies: Retrospective Real-World Analysis at a Comprehensive Cancer Center

Alejandro Recio Boiles, MD, Ali McBride, PharmD,MS, Hani M. Babiker, MD, Nimer Alsaid, PhD MS, PharmD, Ivo Abraham, PhD RN, Emad Elquza, MD MBA

Blood (2018) 132 (Supplement 1): 5057.

https://doi.org/10.1182/blood-2018-99-114204

Published: 2018

Journal Articles

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Ali McBride, PharmD, MS, Sanjeev Balu, PhD, Kim Campbell, PharmD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2018-99-113283

Published: 2018

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Neda Alrawashdh, Nimer Alkhatib, Ali McBride, PharmD, MS, Daniel Persky, MD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2018-99-112619

Published: 2018

Journal Articles

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Ali McBride, PharmD,MS, Andriy Krendyukov, MD MBA, Nicola Mathieson, Kim Campbell, PharmD, Sanjeev Balu, PhD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2018-99-116315

Published: 2018

Journal Articles

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Ali McBride, PharmD,MS, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, PhD RN, Sanjeev Balu

Blood (2017) 130 (Supplement 1): 3380.

https://doi.org/10.1182/blood.V130.Suppl_1.3380.3380

Published: 2017

Journal Articles

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 3400.

https://doi.org/10.1182/blood.V130.Suppl_1.3400.3400

Published: 2017

Journal Articles

Efficacy and Toxicity Profile of Carfilzomib Based Regimens for Treatment of Multiple Myeloma, a Systematic Review

Adeela Mushtaq, MD, Azka Latif, MD, Vikas Kapoor, MD, Faiza Hassan Warraich, MD, Sami Ullah Warraich, MBBS, Ahmad Iftikhar, MD, Pavan Tenneti, MD, Raahem Nayab Zafar, BS, Atlantis Dawn Russ, MD PhD, Ivo Abraham, PhD RN, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5413.

https://doi.org/10.1182/blood.V130.Suppl_1.5413.5413

Published: 2017

Journal Articles

Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 4711.

https://doi.org/10.1182/blood.V130.Suppl_1.4711.4711

Published: 2017

Journal Articles

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, Mok Oh, Daniel Persky, MD, Faiz Anwer, MD, Leslie Andritsos, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4678.

https://doi.org/10.1182/blood.V130.Suppl_1.4678.4678

Published: 2017

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, HyunJung Kim, Mok Oh, Leslie Andritsos, MD, Faiz Anwer, MD, Daniel Persky, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4679.

https://doi.org/10.1182/blood.V130.Suppl_1.4679.4679

Published: 2017

Journal Articles

Evaluation of Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism for Inherited Thrombophilia Disorders

Ali McBride, PharmD,MS, Reem Diri, PharmD, Ravitharan Krishnadasan, MD, Pavani Chalasani, MD MPH, Ivo Abraham, PhD RN, Chris Campen, PharmD

Blood (2016) 128 (22): 5007.

https://doi.org/10.1182/blood.V128.22.5007.5007

Published: 2016

Journal Articles

Evaluation of Efficacy and Safety of Direct Oral Anticoagulants (DOACS) in the Treatment of Venous Thromboembolism in Cancer Patients

Ali McBride, PharmD,MS, Reem Diri, PharmD, Chris Campen, PharmD, Ivo Abraham, PhD RN

Blood (2016) 128 (22): 5016.

https://doi.org/10.1182/blood.V128.22.5016.5016

Published: 2016

NARROW

Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Economic Evaluation of Daratumumab and Pomalidomide and Dexamethasone Versus Isatuximab and Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Recurrent Venous Thromboembolism (VTE), Major Bleeding (MB), and Associated Cost of Treatment with Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulant (DOAC) in High Risk Patients with Gastrointestinal (GI) Malignancies: Retrospective Real-World Analysis at a Comprehensive Cancer Center

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Efficacy and Toxicity Profile of Carfilzomib Based Regimens for Treatment of Multiple Myeloma, a Systematic Review

Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Evaluation of Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism for Inherited Thrombophilia Disorders

Evaluation of Efficacy and Safety of Direct Oral Anticoagulants (DOACS) in the Treatment of Venous Thromboembolism in Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only